Invitation to press- and analyst conference
(Thomson Reuters ONE) - Biovitrum AB (publ) will hold a press conference today to present theproposed combination with Swedish Orphan International AB.Time: 11:00 (CET), today Thursday November 5, 2009Venue: Carnegie's offices, Regeringsgatan 56 inStockholm, SwedenTo follow the press conference over telephone, please use thefollowing dial-in number: + 46 (0) 850 520 270.Conference call at 16:00 (CET)A conference call for investors and media in other time zones will beheld in English this afternoon at 16:00 (CET). Presentation materialswill be available on our web site: www.biovitrum.com, where it alsowill be possible to listen to the conference call afterwards. Thedial-in number for the telephone conference is + 46 (0) 850 520 270.Welcome!Erik Kinnman, EVP Investor RelationsPhone: +46 (0) 8 697 21 50, erik.kinnman(at)biovitrum.comAbout BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. The company has revenues of approximately SEK 1.2billion and around 400 employees. The company head office is locatedin Sweden and it is listed on the Stockholm OMX Nordic Exchange. Formore information please visit www.biovitrum.comhttp://hugin.info/134557/R/1352888/327553.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 05.11.2009 - 10:22 Uhr
Sprache: Deutsch
News-ID 7965
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Invitation to press- and analyst conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
